Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is Vestal Point Capital LP's 2nd Largest Position

Vestal Point Capital LP decreased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 40.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 900,000 shares of the specialty pharmaceutical company's stock after selling 600,000 shares during the quarter. Jazz Pharmaceuticals accounts for about 7.6% of Vestal Point Capital LP's holdings, making the stock its 2nd biggest holding. Vestal Point Capital LP owned about 1.49% of Jazz Pharmaceuticals worth $100,269,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Versant Capital Management Inc lifted its position in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after acquiring an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at $29,000. EverSource Wealth Advisors LLC boosted its position in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after purchasing an additional 97 shares in the last quarter. GAMMA Investing LLC grew its holdings in Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock valued at $31,000 after buying an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on JAZZ. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Piper Sandler reiterated an "overweight" rating and set a $163.00 target price (down from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Needham & Company LLC reaffirmed a "buy" rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. StockNews.com raised shares of Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, August 1st. Finally, Royal Bank of Canada raised their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a research note on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $175.33.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded down $1.05 during midday trading on Friday, hitting $121.59. The company's stock had a trading volume of 286,839 shares, compared to its average volume of 675,459. The stock's 50-day moving average price is $114.66 and its 200 day moving average price is $111.07. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market cap of $7.35 billion, a price-to-earnings ratio of 17.13, a PEG ratio of 1.03 and a beta of 0.57. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the company's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,110 shares of company stock worth $720,160. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.